Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors.
Lowndes SA, Adams A, Timms A, Fisher N, Smythe J, Watt SM, Joel S, Donate F, Hayward C, Reich S, Middleton M, Mazar A, Harris AL.
Lowndes SA, et al. Among authors: harris al.
Clin Cancer Res. 2008 Nov 15;14(22):7526-34. doi: 10.1158/1078-0432.CCR-08-0315.
Clin Cancer Res. 2008.
PMID: 19010871
Clinical Trial.